Disclosed herein are aqueous pharmaceutical formulations comprising denosumab or another human anti-RANKL monoclonal antibody or portion thereof, and characteristics of pH, buffer systems, and amino acid aggregation inhibitors. Also disclosed are presentation of the formulation for use, e.g. in a single-use vial, single-use syringe, or glass container, methods of using the formulations and articles for preventing or treating diseases, and related kits.

Provided herein are formulations for the safe and effective topical delivery of buffering agents. The invention includes formulations and methods to balance electrolytes, overcome cation overload, and/or deliver buffers with and without counterions that can be combined in a single use formulation or alternatively in separately applied formulations. Also provided are methods of using the formulations for the treatment of a wide variety of disorders relating to electrolyte imbalance, cation overload, or related conditions.

The present invention discloses pharmaceutical-grade ferric organic compounds having enhanced dissolution rate. These ferric organic compounds, including but are not limited to ferric citrate, are useful for treating chronic kidney disease.

Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones represented by the Formula (I): ##STR00001## wherein Ar, R.sub.1-R.sub.6 are defined herein. Compounds having Formula (I) are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity.

The present invention provides compounds represented by formula (1) below and pharmacologically acceptable salts thereof:

##STR00001##

wherein R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are as defined in the claims.

The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.

Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, such as cinacalcet or a salt thereof, and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.

The present invention relates to mixtures of serine or threonine together with at least one further amino acid or amino acid derivative and with at least one calcium salt or its hydrate and methods including this mixture including specific mixtures of such components and a formulations consisting of the mixture and a solvent.

The present invention relates to mixtures of serine or threonine together with at least one further amino acid or amino acid derivative and with at least one calcium salt or its hydrate and methods including this mixture including specific mixtures of such components and a formulations consisting of the mixture and a solvent.

The present invention relates to: a pharmaceutical composition for preventing or treating vascular or cardiac valvular calcification, containing a thiamine derivative or a pharmaceutically acceptable salt thereof; and a food composition for alleviating vascular or cardiac valvular calcification, containing a thiamine derivative or a salt thereof, and the compositions of the present invention can be effectively used for a use of preventing, treating or alleviating vascular or cardiac valvular calcification.